Highlights 

  • Arrowhead Pharmaceuticals Inc. receives its first FDA approval for REDEMPLO. 
  • REDEMPLO is approved for adult patients with familial chylomicronemia syndrome, a rare genetic disorder. 
  • The therapy uses Arrowhead’s TRiM platform to reduce triglycerides via gene silencing. 
  • Phase 3 PALISADE data showed meaningful triglyceride reduction and fewer acute pancreatitis events. 
  • Approval marks Arrowhead’s transition into a commercial-stage biopharma company. 

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) has achieved a major regulatory milestone as the U.S.Food and Drug Administration approvedREDEMPLO (plozasiran) for the treatment of adult patients with familial chylomicronemia syndrome. This marks the company’s first FDA-approved medicine and represents a pivotal step in its evolution from a development-stage biotech to a commercial biopharmaceutical enterprise. 

FCS is an ultra-rare genetic disorder in which patients experience triglyceride levels that can be 10 to 100 times above the normal range. Elevated triglycerides significantly increase the risk of recurrent and life-threatening pancreatitis, often requiring long-term clinical management and frequent hospitalizations. 

TRiM Platform Enables Gene Silencing to Lower Triglycerides 

REDEMPLO is a small interfering RNA (siRNA) therapy designed with Arrowhead’s proprietary TRiM platform. It works by silencing disease-driving genes that contribute to dangerously high triglyceride levels in FCS patients. 

The treatment is administered as a 25 mg subcutaneous injection once every three months, offering a convenient and self-administered therapeutic option. This dosing schedule provides meaningful patient flexibility compared to more frequent administration regimens seen in other rare disease therapies. 

The therapy’s approval is based on outcomes from PALISADE, a randomized, placebo-controlled Phase 3 study evaluating efficacy and safety in adult FCS patients. According to Arrowhead, the trial demonstrated substantial reductions in triglyceride levels from baseline, along with a reduction in the numerical incidence of acute pancreatitis when compared with placebo. 

Phase 3 PALISADE Data Support Approval and Commercial Launch 

Safety findings from PALISADE were described as generally manageable, supporting outpatient use and self-injection without the need for extensive in-clinic monitoring. The company noted that additional data from the trial will be presented at upcoming scientific conferences, which may provide further insights into REDEMPLO’s long-term impact, safety considerations, and patient-reported outcomes. 

Arrowhead expects REDEMPLO to become available in the U.S. before the end of the year, marking the company’s official entry into commercial operations. The approval also highlights the increasing clinical relevance of RNA-based therapies in addressing genetic disorders with limited treatment options. 

Arrowheads’ shares previously closed at USD 40.47. 

Conclusion 

The FDA approval of REDEMPLO represents a landmark moment for Arrowhead Pharmaceuticals. By bringing its first therapy to market, Arrowhead solidifies its presence in the commercial biopharma landscape while offering FCS patients a new treatment option with meaningful clinical potential. With PALISADE data soon to be presented and commercial availability imminent, the approval sets the stage for expanded attention on Arrowhead’s broader RNA-based therapeutic pipeline. 

Also read - Genmab (NASDAQ:GMAB) Wins Full FDA Clearance for EPKINLY + R2 in Follicular Lymphoma